对抗……的抗生素替代品
Alternatives to Antibiotics against .
作者信息
Broncano-Lavado Antonio, Senhaji-Kacha Abrar, Santamaría-Corral Guillermo, Esteban Jaime, García-Quintanilla Meritxell
机构信息
Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Av. Reyes Católicos, 2, 28040 Madrid, Spain.
CIBERINFEC-Infectious Diseases CIBER, Madrid, Spain.
出版信息
Antibiotics (Basel). 2022 Sep 28;11(10):1322. doi: 10.3390/antibiotics11101322.
Abstract
complex is extremely difficult to treat. Intrinsic and acquired bacterial resistance makes this species one of the most challenging pathogens and treatments last from months to years, associated with potential risky antibiotic toxicity and a high number of failures. Nonantibiotic antimicrobial agents against this microorganism have recently been studied so as to offer an alternative to current drugs. This review summarizes recent research on different strategies such as host modulation using stem cells, photodynamic therapy, antibiofilm therapy, phage therapy, nanoparticles, vaccines and antimicrobial peptides against both in vitro and in vivo.
摘要
该复合体极难治疗。内在和获得性细菌耐药性使该物种成为最具挑战性的病原体之一，治疗持续数月至数年，伴有潜在的危险抗生素毒性和大量治疗失败情况。最近对针对这种微生物的非抗生素抗菌剂进行了研究，以便为现有药物提供替代方案。本综述总结了最近关于不同策略的研究，如使用干细胞进行宿主调节、光动力疗法、抗生物膜疗法、噬菌体疗法、纳米颗粒、疫苗和抗菌肽，包括体外和体内研究。
相似文献
1
Alternatives to Antibiotics against .
Antibiotics (Basel). 2022 Sep 28;11(10):1322. doi: 10.3390/antibiotics11101322.
2
Antimycobacterial activity of nonantibiotics associated with the polypharmacy of cystic fibrosis (CF) against mycobacterium abscessus.
Int J Mycobacteriol. 2018 Oct-Dec;7(4):358-360. doi: 10.4103/ijmy.ijmy_142_18.
3
Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus.
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0067621. doi: 10.1128/AAC.00676-21.
4
Alternative and Experimental Therapies of Infections.
Int J Mol Sci. 2020 Sep 16;21(18):6793. doi: 10.3390/ijms21186793.
5
In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Microb Drug Resist. 2016 Mar;22(2):172-8. doi: 10.1089/mdr.2015.0134. Epub 2015 Oct 15.
6
Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.
Antimicrob Agents Chemother. 2019 Jul 25;63(8). doi: 10.1128/AAC.00665-19. Print 2019 Aug.
7
In Vitro Efficacy of Free and Nanoparticle Formulations of Gallium(III) meso-Tetraphenylporphyrine against Mycobacterium avium and Mycobacterium abscessus and Gallium Biodistribution in Mice.
Mol Pharm. 2018 Mar 5;15(3):1215-1225. doi: 10.1021/acs.molpharmaceut.7b01036. Epub 2018 Feb 16.
8
Antimicrobial properties of basidiomycota macrofungi to isolated from patients with cystic fibrosis.
Int J Mycobacteriol. 2019 Jan-Mar;8(1):93-97. doi: 10.4103/ijmy.ijmy_167_18.
9
Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01947-20.
10
Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus.
Microbiol Spectr. 2022 Feb 23;10(1):e0132121. doi: 10.1128/spectrum.01321-21. Epub 2022 Jan 12.
引用本文的文献
1
P3MA: A Promising Mycobacteriophage Infecting .
Antibiotics (Basel). 2025 Aug 6;14(8):801. doi: 10.3390/antibiotics14080801.
2
Potency of all-D amino acid antimicrobial peptides derived from the bovine rumen microbiome on tuberculous and non-tuberculous mycobacteria.
Curr Res Microb Sci. 2025 Apr 22;8:100395. doi: 10.1016/j.crmicr.2025.100395. eCollection 2025.
3
Clinical Trials involving : An update.
Ulster Med J. 2025 Apr;94(1):28-30. Epub 2025 Apr 30.
4
Novel Synthetic Peptide Agelaia-12 Has Improved Activity Against Complex.
Pathogens. 2024 Nov 13;13(11):994. doi: 10.3390/pathogens13110994.
5
Design and Synthesis of Novel Amino and Acetamidoaurones with Antimicrobial Activities.
Antibiotics (Basel). 2024 Mar 26;13(4):300. doi: 10.3390/antibiotics13040300.
6
Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria.
Rev Esp Quimioter. 2024 Jun;37(3):266-269. doi: 10.37201/req/014.2024. Epub 2024 Apr 11.
7
Effect of multidrug therapy on the prognosis of Mycobacterium avium complex pulmonary disease.
Sci Rep. 2024 Feb 23;14(1):4438. doi: 10.1038/s41598-024-55135-0.
8
Promising antibacterial efficacy of arenicin peptides against the emerging opportunistic pathogen Mycobacterium abscessus.
J Biomed Sci. 2024 Jan 29;31(1):18. doi: 10.1186/s12929-024-01007-8.
9
Molecular Identification of Strains within the Complex and Determination of Resistance to Macrolides and Aminoglycosides.
Pol J Microbiol. 2023 Dec 16;72(4):491-506. doi: 10.33073/pjm-2023-048. eCollection 2023 Dec 1.
10
Mycothione reductase as a potential target in the fight against infections.
mSphere. 2024 Jan 30;9(1):e0066923. doi: 10.1128/msphere.00669-23. Epub 2023 Dec 12.
本文引用的文献
1
High-Throughput Screening Identifies Synthetic Peptides with Antibacterial Activity against and Serum Stability.
ACS Omega. 2022 Jun 27;7(27):23967-23977. doi: 10.1021/acsomega.2c02844. eCollection 2022 Jul 12.
2
Nebulized Bacteriophage in a Patient With Refractory Lung Disease.
Open Forum Infect Dis. 2022 Apr 12;9(7):ofac194. doi: 10.1093/ofid/ofac194. eCollection 2022 Jul.
3
Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease.
Clin Infect Dis. 2023 Jan 6;76(1):103-112. doi: 10.1093/cid/ciac453.
4
Viruses to the rescue-Use of bacteriophage to treat resistant pulmonary infections.
Cell. 2022 May 26;185(11):1807-1808. doi: 10.1016/j.cell.2022.04.037.
5
Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection.
Cell. 2022 May 26;185(11):1860-1874.e12. doi: 10.1016/j.cell.2022.04.024. Epub 2022 May 13.
6
2-Aminoimidazoles Inhibit Biofilms in a Zinc-Dependent Manner.
Int J Mol Sci. 2022 Mar 9;23(6):2950. doi: 10.3390/ijms23062950.
7
ALA_PDT Promotes Ferroptosis-Like Death of and Antibiotic Sterilization via Oxidative Stress.
Antioxidants (Basel). 2022 Mar 14;11(3):546. doi: 10.3390/antiox11030546.
8
In vitro study of the effect of ALA-PDT on Mycobacterium abscessus and its antibiotic susceptibility.
Photodiagnosis Photodyn Ther. 2022 Jun;38:102802. doi: 10.1016/j.pdpdt.2022.102802. Epub 2022 Mar 14.
9
Antibacterial peptide RP557 increases the antibiotic sensitivity of Mycobacterium abscessus by inhibiting biofilm formation.
Sci Total Environ. 2022 Feb 10;807(Pt 3):151855. doi: 10.1016/j.scitotenv.2021.151855. Epub 2021 Nov 20.
10
Assessment of in vitro activities of novel modified antimicrobial peptides against clarithromycin resistant Mycobacterium abscessus.
PLoS One. 2021 Nov 15;16(11):e0260003. doi: 10.1371/journal.pone.0260003. eCollection 2021.
Zotero 插件